期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 14, 期 4, 页码 219-227出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-019-00530-y
关键词
Translation; Translation inhibitor; 4E-BP1; eIF4A; eIF4E; Omacetaxine; Umbralisib; Selinexor
Purpose of Review To highlight recent results in targeting mRNA translation and discuss the results and prospects of translation inhibitors in cancer therapy. Recent Findings Until recently, inhibitors of mRNA translation have been thought to likely lack a therapeutic window. In 2012, the Food and Drug Administration (FDA) approved omacetaxine mepesuccinate (homoharringtonine) for the treatment of adults with chronic myelogenous leukemia (CML) who are resistant to at least two tyrosine kinase inhibitors. Since then, a few drugs, notably tomivosertib (eFT-508), selinexor (KPT-330), and ribavirin, have entered clinical trials. These drugs are known to inhibit mRNA translation. More recently, a number of interesting studies report that discrete subsets of proteins in cancer cells may be selectively targeted at the translation step, through inhibiting signals such as phospho-4E-BP1, eIF4A, and eIF4E. Promising therapies using these strategies have demonstrated potent anti-tumor activity in preclinical cancer models. Summary The growing number of translation inhibitors with diverse mechanisms, coupled with emerging insights into translational regulation of different cancer-promoting genes, suggests a bright new horizon for the field of therapeutic targeting of mRNA translation in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据